Professional
Added to YB: 2024-08-22
Pitch date: 2024-07-20
TMDX [bullish]
TransMedics Group, Inc.
-14.57%
current return
Author Info
No bio for this author
Company Info
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Market Cap
$4.5B
Pitch Price
$148.41
Price Target
N/A
Dividend
N/A
EV/EBITDA
35.52
P/E
51.63
EV/Sales
7.99
Sector
Health Care Equipment and Supplies
Category
growth
Invesco Discovery Fund Portfolio Holding: TransMedics Group, Inc.
TMDX: TransMedics delivers strong Q results, raises 2024 guidance above consensus. Unique organ transplant service expands US market, increasing donor-to-recipient efficiency. Growth in end-stage organ failure therapy across multiple diseases.
Read full article (1 min)